Kiromic Biopharma Inc
OTC:KRBP
Kiromic Biopharma Inc
Kiromic Biopharma, Inc. operates as a biotechnology company, which engages in the development of cancer engineered immunotherapies. The company is headquartered in Houston, Texas and currently employs 59 full-time employees. The company went IPO on 2020-10-16. The firm is focused on discovering, developing and commercializing immuno-oncology applications through its product pipeline. The company is developing a range of product candidates for the treatment of blood cancers and solid tumors. Its lead product candidates include ALEXIS-PRO-1 and ALEXIS-ISO-1. The firm is developing its brand of chimeric antigen receptor (CAR) T cell product candidates known as ALEXIS (Allogenic Lead Exogenous Isoforms). The ALEXIS platform of products has been designed to incorporate its Diamond target discovery platform into an off the shelf gamma delta T cell therapy that address the metastatic and progressive locally advanced solid malignancies, including ovarian, malignant pleural mesothelioma and multiple other indications as well. Its Diamond is a computational platform and a neural network that can identify new cancer immunological targets for T cells and B cells.
Kiromic Biopharma, Inc. operates as a biotechnology company, which engages in the development of cancer engineered immunotherapies. The company is headquartered in Houston, Texas and currently employs 59 full-time employees. The company went IPO on 2020-10-16. The firm is focused on discovering, developing and commercializing immuno-oncology applications through its product pipeline. The company is developing a range of product candidates for the treatment of blood cancers and solid tumors. Its lead product candidates include ALEXIS-PRO-1 and ALEXIS-ISO-1. The firm is developing its brand of chimeric antigen receptor (CAR) T cell product candidates known as ALEXIS (Allogenic Lead Exogenous Isoforms). The ALEXIS platform of products has been designed to incorporate its Diamond target discovery platform into an off the shelf gamma delta T cell therapy that address the metastatic and progressive locally advanced solid malignancies, including ovarian, malignant pleural mesothelioma and multiple other indications as well. Its Diamond is a computational platform and a neural network that can identify new cancer immunological targets for T cells and B cells.
